Description
Balstilimab is a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1. An immune checkpoint inhibitor, balstilimab binds to PD-1, and thereby blocks its binding to the PD-L1, that prevents the activation of its downstream signaling pathways. It is under investigation and trials for several indications include cervical cancer.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Balstilimab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Balstilimab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Balstilimab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Balstilimab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!